“We believe the ability to work with just two drops of blood, plus the fast time-to-results and the reduction in operator overhead provided by our FDA-cleared moderate-complexity analyzer, will be highly attractive to providers.” —Yossi Pollak, CEO, Sight Diagnostics, Ltd. CEO SUMMARY: For 70 years, the Coulter Principle has been a bedrock technology in hematology. …
Two-Drop ‘Digital CBC’ Enters U.S. Market with FDA Clearance Read More »
